RINVOQ (upadacitinib) has been approved by the European Commission for the treatment of adult patients with moderately to severely active ulcerative colitis who 26 July 2022
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adults with 19 July 2022
Qulipta (atogepant) has taken another step on its way to becoming a significant force in the world of calcitonin gene-related peptide (CGRP) receptor blocking m 18 July 2022
The European Medicines Agency has identified measures to address medicine shortages during public health emergencies, following a meeting of a steering group de 8 July 2022
The European Commission (EC) has approved Sanofi’s Xenpozyme (olipudase alfa) as the first and only enzyme replacement therapy to treat non-central nervous syst 28 June 2022
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.